zotarolimus

Background New-generation coronary stents that release zotarolimus or everolimus have been shown to reduce the risk of restenosis.

New England Journal of Medicine Serruys 2010

Methods In this multicenter, noninferiority trial with minimal exclusion criteria, we randomly assigned 2292 patients to undergo treatment with coronary stents releasing either zotarolimus or everolimus.

New England Journal of Medicine Serruys 2010

The zotarolimus-eluting stent was noninferior to the everolimus-eluting stent with respect to the primary end point, which occurred in 8.2% and 8.3% of were no significant between-group differences in the rate of death from cardiac causes, any myocardial infarction, or revascularization.

New England Journal of Medicine Serruys 2010

The zotarolimus-eluting stent was also noninferior regarding the degree (±SD) of in-stent stenosis (21. 65±14.42% for zotarolimus vs. 19. 76±14.64% for everolimus, P = 0.04 for noninferiority).

New England Journal of Medicine Serruys 2010

At 13 months, the new-generation zotarolimus-eluting stent was found to be noninferior to the everolimus-eluting stent in a population of patients who had minimal exclusion

New England Journal of Medicine Serruys 2010

The rate of stent thrombosis was 2.3% in the zotarolimus-stent group and 1.5% in the everolimus-stent group (P = 0.17).

New England Journal of Medicine Serruys 2010

In-stent late lumen loss was 0. 27±0.43 mm in the zotarolimus-stent group versus 0. 19±0.40 mm in the everolimus-stent group

New England Journal of Medicine Serruys 2010

Endeavor zotarolimus-eluting coronary stent gets market green light

theHeart.org 2008

Coupled with the MicroTrac delivery system, continuous sinusoid technology improves deliverability without compromising other important stent's conformability - the ability of the stent to conform to the natural shape of the vessel and maintain apposition to the vessel wall after inflation with the balloon drug-eluting stents to address the spectrum of clinical need for patients with drug-eluting stent (DES) combines continuous sinusoid technology with two key elements of the original Resolute DES: the cytostatic antiproliferative drug zotarolimus and the highly biocompatible BioLinx polymer.

THE MEDICAL NEWS 2010

Coupled with the MicroTrac delivery system, continuous sinusoid technology improves deliverability without compromising other important stent's conformability - the ability of the stent to conform to the natural shape of the vessel and maintain apposition to the vessel wall after inflation with the balloon drug-eluting stents to address the spectrum of clinical need for patients with drug-eluting stent (DES) combines continuous sinusoid technology with two key elements of the original Resolute DES: the cytostatic antiproliferative drug zotarolimus and the highly biocompatible BioLinx polymer.

THE MEDICAL NEWS 2010